# A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

Source: https://onco.cc/trials/nct06758557/  
OnCo record `nct06758557` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin in endometrial cancer, run by Huabo Biopharm Co., Ltd., now recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT06758557 by Huabo Biopharm Co., Ltd., with 282 participants planned, started 2024-01-31 and due to reach its primary completion in 2025-10-31. Interventions recorded: HB0025, Pemetrexed, Paclitaxel, Carboplatin. Conditions listed: Advanced NSCLC, Advanced Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06758557
- Phase: 1/2
- Setting: A Multicenter, Open Phase Ib/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of HB0025 Injection Combined With Chemotherapy in Patients With Advanced Solid Tumor
- Sponsor: Huabo Biopharm Co., Ltd.
- Enrolled: 282

## Sources

- ClinicalTrials.gov NCT06758557: https://clinicaltrials.gov/study/NCT06758557

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct06758557.json